Sara Benitez Majano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Benitez Majano has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Bernard Rachet
London School of Hygiene and Tropical Medicine
9 shared publications - Chiara Di Girolamo
Centre for Biostatistics, Epidemiology, and Public Health, Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy
4 shared publications - Michel Philippe Coleman
Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine , Keppel Street, London WC1E 7HT
4 shared publications - Sarah Walters
London School of Hygiene and Tropical Medicine
4 shared publications - Melanie Morris
Clinical Effectiveness Unit, Royal College of Surgeons of England, London, London, UK
3 shared publications Aimilia Exarchakou
Inequalities in Cancer Outcomes Network, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
2 shared publications
Latest Publications
- Open Access
Assessing ethnic differences in age-standardised net survival of eight common cancer: an English population-based study
Background: We examined ethnic differences in age-standardised net survival (ANS) for eight common cancers diagnosed in England between 2010 and 2019. Methods: Analyses included 247,428 patients aged ≥40 years diagnosed with breast, prostate, lung, colorectal, cervical, ovarian, myeloma, and oesophagogastric cancers. Net survival was estimated at one, three, and five years using the Pohar-Perme estimator and age-standardised with International Cancer Survival Standards weights across four age bands. Results: Compared with White patients, Black patients had higher ANS for lung and prostate cancers at all time points, for myeloma at one year, and for oesophagogastric cancer at one and three years. However, they had lower ANS for breast cancer at three years. Asian patients had higher ANS for lung, prostate, and oesophagogastric cancers at all time points, and for other sites at varying follow-up times. Patients in the Mixed group had higher ANS for most cancers, whereas those in the Other ethnic group generally had lower ANS compared with White patients. Conclusions: Ethnic minority groups in England do not consistently experience poorer cancer survival, with varying patterns observed by cancer site. Universal healthcare access may reduce disparities observed elsewhere, highlighting the importance of context-specific research and public policy.
Open AccessAssessing ethnic differences in age-standardised net survival of eight common cancer: an English population-based study
Background: We examined ethnic differences in age-standardised net survival (ANS) for eight common cancers diagnosed in England between 2010 and 2019. Methods: Analyses included 247,428 patients aged ≥40 years diagnosed with breast, prostate, lung, colorectal, cervical, ovarian, myeloma, and oesophagogastric cancers. Net survival was estimated at one, three, and five years using the Pohar-Perme estimator and age-standardised with International Cancer Survival Standards weights across four age bands. Results: Compared with White patients, Black patients had higher ANS for lung and prostate cancers at all time points, for myeloma at one year, and for oesophagogastric cancer at one and three years. However, they had lower ANS for breast cancer at three years. Asian patients had higher ANS for lung, prostate, and oesophagogastric cancers at all time points, and for other sites at varying follow-up times. Patients in the Mixed group had higher ANS for most cancers, whereas those in the Other ethnic group generally had lower ANS compared with White patients. Conclusions: Ethnic minority groups in England do not consistently experience poorer cancer survival, with varying patterns observed by cancer site. Universal healthcare access may reduce disparities observed elsewhere, highlighting the importance of context-specific research and public policy.
- Open Access
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Exploring the Use and Reporting of Cancer Registry Data by the Caribbean Region: A Scoping Review
PURPOSE: To conduct a scoping review to identify publications that used data from Caribbean cancer registries (CRs) to characterize the type of information disseminated and identify knowledge gaps. METHODS: We searched PubMed, Scopus, Web of Science: Core Collection and SciELO, and Latin American and Caribbean Literature on Health Sciences for articles published in English, French, Dutch, or Spanish between January 2012 and May 2023. Articles that used data from a CR located in one or more Caribbean country/territory were included. In Covidence, a two-step screening process at title/abstract and full text was completed by two reviewers independently. Data were extracted from each included article independently by two reviewers using Covidence. A gray literature search of online and paper reports using CR data was also conducted to supplement the literature searches. RESULTS: A total of 126 articles met the inclusion criteria and reported CR data from 1958 to 2018. Of the 33 Caribbean countries/territories included, 12 had at least one publication. Most publications (95%) used data from population-based CRs (PBCRs). Three countries/territories with PBCRs had <3 publications, and three had none. Breast, cervical, and colorectal were the most reported cancers. Ten of 14 (71%) countries/territories with a PBCR had at least one cancer incidence report available from the past 5 years. CONCLUSION: Caribbean CRs have contributed substantially to the peer-reviewed literature, but this is limited to fewer than half of the Caribbean countries and primarily those with a PBCR. Efforts are needed to establish and support PBCRs to produce high-quality data and to bridge the gap between the collection and dissemination of CR data to address key knowledge gaps, prioritize research questions, and inform cancer control policies.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Open AccessExploring the Use and Reporting of Cancer Registry Data by the Caribbean Region: A Scoping Review
PURPOSE: To conduct a scoping review to identify publications that used data from Caribbean cancer registries (CRs) to characterize the type of information disseminated and identify knowledge gaps. METHODS: We searched PubMed, Scopus, Web of Science: Core Collection and SciELO, and Latin American and Caribbean Literature on Health Sciences for articles published in English, French, Dutch, or Spanish between January 2012 and May 2023. Articles that used data from a CR located in one or more Caribbean country/territory were included. In Covidence, a two-step screening process at title/abstract and full text was completed by two reviewers independently. Data were extracted from each included article independently by two reviewers using Covidence. A gray literature search of online and paper reports using CR data was also conducted to supplement the literature searches. RESULTS: A total of 126 articles met the inclusion criteria and reported CR data from 1958 to 2018. Of the 33 Caribbean countries/territories included, 12 had at least one publication. Most publications (95%) used data from population-based CRs (PBCRs). Three countries/territories with PBCRs had <3 publications, and three had none. Breast, cervical, and colorectal were the most reported cancers. Ten of 14 (71%) countries/territories with a PBCR had at least one cancer incidence report available from the past 5 years. CONCLUSION: Caribbean CRs have contributed substantially to the peer-reviewed literature, but this is limited to fewer than half of the Caribbean countries and primarily those with a PBCR. Efforts are needed to establish and support PBCRs to produce high-quality data and to bridge the gap between the collection and dissemination of CR data to address key knowledge gaps, prioritize research questions, and inform cancer control policies.
- Open Access
- 4 February 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 55
Accelerating the elimination of cervical cancer: cross-sectional examination of cancer prevention and control in Latin America and the Caribbean
- 4 February 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 55
Open AccessAccelerating the elimination of cervical cancer: cross-sectional examination of cancer prevention and control in Latin America and the Caribbean
- 19 January 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (6) , 677-687
Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong
Background Previous evidence suggests a potential protective effect of warfarin against cancer, compared to non-users. However, it may be prone to immortal time bias and residual confounding. Objective We aimed to examine the association between cancer and warfarin, compared with active comparator (direct oral anticoagulants). Methods We conducted studies using population-based databases from England and Hong Kong to investigate the association between warfarin and hazard of cancer using a new-user active-comparator cohort design. People with atrial fibrillation aged ≥ 18 years who had first received anticoagulant treatment during 01/01/2011–31/12/2019 were involved. Results No evidence supported the association between warfarin and hazard of overall cancer, compared with direct oral anticoagulants in both settings (England: hazard ratio [HR] = 1.03, 95% confidence interval [CI] 0.94–1.13; Hong Kong: HR = 0.89, 95% CI 0.79–1.01). A lower hazard of female breast (HR = 0.49, 95% CI 0.30–0.79), ovarian (HR = 0.07, 95% CI 0.01–0.58), and pancreatic (HR = 0.46, 95% CI 0.22–0.96) cancers and a higher hazard of kidney cancer (HR = 3.57, 95% CI 1.64–7.76) were found in Hong Kong, comparing warfarin with direct oral anticoagulants, but these were not replicated in England. Conclusions This study does not find a protective effect of warfarin against cancer versus direct oral anticoagulants. The risks of site-specific cancers including pancreatic, kidney, and sex-specific cancers between oral anticoagulants shown in the Hong Kong setting only may require further investigation in other independent datasets.
- 19 January 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (6) , 677-687
Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong
Background Previous evidence suggests a potential protective effect of warfarin against cancer, compared to non-users. However, it may be prone to immortal time bias and residual confounding. Objective We aimed to examine the association between cancer and warfarin, compared with active comparator (direct oral anticoagulants). Methods We conducted studies using population-based databases from England and Hong Kong to investigate the association between warfarin and hazard of cancer using a new-user active-comparator cohort design. People with atrial fibrillation aged ≥ 18 years who had first received anticoagulant treatment during 01/01/2011–31/12/2019 were involved. Results No evidence supported the association between warfarin and hazard of overall cancer, compared with direct oral anticoagulants in both settings (England: hazard ratio [HR] = 1.03, 95% confidence interval [CI] 0.94–1.13; Hong Kong: HR = 0.89, 95% CI 0.79–1.01). A lower hazard of female breast (HR = 0.49, 95% CI 0.30–0.79), ovarian (HR = 0.07, 95% CI 0.01–0.58), and pancreatic (HR = 0.46, 95% CI 0.22–0.96) cancers and a higher hazard of kidney cancer (HR = 3.57, 95% CI 1.64–7.76) were found in Hong Kong, comparing warfarin with direct oral anticoagulants, but these were not replicated in England. Conclusions This study does not find a protective effect of warfarin against cancer versus direct oral anticoagulants. The risks of site-specific cancers including pancreatic, kidney, and sex-specific cancers between oral anticoagulants shown in the Hong Kong setting only may require further investigation in other independent datasets.
- Open Access
- 22 April 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (4) , 719-730
Assessment of barriers to cancer screening and interventions implemented to overcome these barriers in 27 Latin American and Caribbean countries
There is a gap in the understanding of the barriers to cancer screening participation and complying with downstream management in the Community of Latin American and Caribbean states (CELAC). Our study aimed to assess barriers across the cancer screening pathway from the health system perspective, and interventions in place to improve screening in CELAC. A standardized tool was used to collect information on the barriers across the screening pathway through engagement with the health authorities of 27 member states of CELAC. Barriers were organized in a framework adapted from the Tanahashi conceptual model and consisted of the following dimensions: availability of services, access (covering accessibility and affordability), acceptability, user–provider interaction, and effectiveness of services (which includes governance, protocols and guidelines, information system, and quality assurance). The tool also collected information of interventions in place, categorized in user‐directed interventions to increase demand, user‐directed interventions to increase access, provider‐directed interventions, and policy and system‐level interventions. All countries prioritized barriers related to the information systems, such as the population register not being accurate or complete (N = 19; 70.4%). All countries implemented some kind of intervention to improve cancer screening, group education being the most reported (N = 23; 85.2%). Training on screening delivery was the most referred provider‐directed intervention (N = 19; 70.4%). The study has identified several barriers to the implementation of cancer screening in the region and interventions in place to overcome some of the barriers. Further analysis is required to evaluate the effectiveness of these interventions in achieving their objectives.
- 22 April 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (4) , 719-730
Open AccessAssessment of barriers to cancer screening and interventions implemented to overcome these barriers in 27 Latin American and Caribbean countries
There is a gap in the understanding of the barriers to cancer screening participation and complying with downstream management in the Community of Latin American and Caribbean states (CELAC). Our study aimed to assess barriers across the cancer screening pathway from the health system perspective, and interventions in place to improve screening in CELAC. A standardized tool was used to collect information on the barriers across the screening pathway through engagement with the health authorities of 27 member states of CELAC. Barriers were organized in a framework adapted from the Tanahashi conceptual model and consisted of the following dimensions: availability of services, access (covering accessibility and affordability), acceptability, user–provider interaction, and effectiveness of services (which includes governance, protocols and guidelines, information system, and quality assurance). The tool also collected information of interventions in place, categorized in user‐directed interventions to increase demand, user‐directed interventions to increase access, provider‐directed interventions, and policy and system‐level interventions. All countries prioritized barriers related to the information systems, such as the population register not being accurate or complete (N = 19; 70.4%). All countries implemented some kind of intervention to improve cancer screening, group education being the most reported (N = 23; 85.2%). Training on screening delivery was the most referred provider‐directed intervention (N = 19; 70.4%). The study has identified several barriers to the implementation of cancer screening in the region and interventions in place to overcome some of the barriers. Further analysis is required to evaluate the effectiveness of these interventions in achieving their objectives.
- 30 August 2023
- Vol. 94 (S3) , e2023161
Delays in cancer diagnosis: challenges and opportunities in Europe.
Early cancer diagnosis is a public health priority, but large proportions of patients are diagnosed with advanced disease or as an emergency, even in countries with universal healthcare coverage. The study aimed at examining factors contributing to diagnostic delays and inequalities in cancer care, discussing challenges and opportunities for improving the diagnosis of cancer. We performed a critical review of the literature examining factors contributing to delays and inequalities in cancer diagnosis, published between 2019-2023, in Europe with a specific focus on Italy. Disparities in screening, cancer diagnosis and treatment have been reported in many European countries, with poorer outcomes for some population sub-groups. For example, some Northern regions in Italy have six-times higher screening participation versus Southern regions. In 2019 36% of the Italian population aged 50-74 reported colorectal cancer screening, higher than the EU average (33%), but lower than in countries like Denmark (>60%). In Italy, the EU country with the largest percentage of people aged 65+, incident cancers are expected to rise by 19.6% over two decades. Older age is also associated with multimorbidity, with physical and mental health morbidities possibly affecting cancer diagnostic pathways. For example, colon cancer patients with pre-existing mental health conditions were 28% less likely to have a prompt colonoscopy when presenting with red-flag symptoms, according to recent UK research. Covid-19 has exacerbated pre-existing inequalities, with reductions in scheduled surgery and oncological treatments, especially affecting women, older and less educated individuals. For ensuring appropriate care, it is crucial to better understand how different factors, including physical and mental health morbidities, impact cancer diagnosis. The "NextGenerationEU" program and the "National Recovery and Resilience Plan" (PNNR in Italy) following the Covid-19 pandemic offer opportunities for reducing inequalities, improving cancer care and chronic disease management for ageing populations.
- 30 August 2023
- Vol. 94 (S3) , e2023161
Delays in cancer diagnosis: challenges and opportunities in Europe.
Early cancer diagnosis is a public health priority, but large proportions of patients are diagnosed with advanced disease or as an emergency, even in countries with universal healthcare coverage. The study aimed at examining factors contributing to diagnostic delays and inequalities in cancer care, discussing challenges and opportunities for improving the diagnosis of cancer. We performed a critical review of the literature examining factors contributing to delays and inequalities in cancer diagnosis, published between 2019-2023, in Europe with a specific focus on Italy. Disparities in screening, cancer diagnosis and treatment have been reported in many European countries, with poorer outcomes for some population sub-groups. For example, some Northern regions in Italy have six-times higher screening participation versus Southern regions. In 2019 36% of the Italian population aged 50-74 reported colorectal cancer screening, higher than the EU average (33%), but lower than in countries like Denmark (>60%). In Italy, the EU country with the largest percentage of people aged 65+, incident cancers are expected to rise by 19.6% over two decades. Older age is also associated with multimorbidity, with physical and mental health morbidities possibly affecting cancer diagnostic pathways. For example, colon cancer patients with pre-existing mental health conditions were 28% less likely to have a prompt colonoscopy when presenting with red-flag symptoms, according to recent UK research. Covid-19 has exacerbated pre-existing inequalities, with reductions in scheduled surgery and oncological treatments, especially affecting women, older and less educated individuals. For ensuring appropriate care, it is crucial to better understand how different factors, including physical and mental health morbidities, impact cancer diagnosis. The "NextGenerationEU" program and the "National Recovery and Resilience Plan" (PNNR in Italy) following the Covid-19 pandemic offer opportunities for reducing inequalities, improving cancer care and chronic disease management for ageing populations.
- Open Access
- 18 October 2022
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 6 (5)
Changing patterns of multidisciplinary team treatment, early mortality, and survival in colorectal cancer
This study reports early mortality and survival from colorectal cancer in relation to the pattern of treatments delivered by the multidisciplinary team (MDT) meeting at a high-volume institution in England over 14 years. All patients diagnosed with colorectal cancer and discussed during MDT meetings from 2003 to 2016 at a single institution were reviewed. Three time intervals (2003–2007, 2008–2012, and 2013–2016) were compared regarding initial surgical management (resection, local excision, non-resection surgery, and no surgery), initial oncological therapy, 90-day mortality, and crude 2-year survival for the whole cohort. Sub-analyses were performed according to age greater or less than 80 years. The MDT managed 4617 patients over 14 years (1496 in the first interval and 1389 in the last). Over this time, there was a reduction in emergency resections from 15.5 per cent to 9.0 per cent (P < 0.0001); use of oncological therapies increased from 34.6 per cent to 41.6 per cent (P < 0.0001). The 90-day mortality after diagnosis of colorectal cancer dropped from 14.8 per cent to 10.7 per cent (P < 0.001) and 2-year survival improved from 58.6 per cent to 65 per cent (P < 0.001). Among patients aged 80 years or older (425 and 446, in the first and last intervals respectively) there was, in addition, a progressive increase in ‘no surgery’ rate from 33.6 per cent to 50.2 per cent (P < 0.0001) and a reduction in elective resections from 42.4 per cent to 33.9 per cent (P = 0.010). The 90-day mortality after elective resection fell from 10.0 per cent (18 of 180) to 3.3 per cent (5 of 151; P = 0.013). Survival from colorectal cancer improved significantly over 14 years. Among patients aged ≥80 years, major changes in the type of treatment delivered were associated with a decrease in postoperative mortality.
- 18 October 2022
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 6 (5)
Open AccessChanging patterns of multidisciplinary team treatment, early mortality, and survival in colorectal cancer
This study reports early mortality and survival from colorectal cancer in relation to the pattern of treatments delivered by the multidisciplinary team (MDT) meeting at a high-volume institution in England over 14 years. All patients diagnosed with colorectal cancer and discussed during MDT meetings from 2003 to 2016 at a single institution were reviewed. Three time intervals (2003–2007, 2008–2012, and 2013–2016) were compared regarding initial surgical management (resection, local excision, non-resection surgery, and no surgery), initial oncological therapy, 90-day mortality, and crude 2-year survival for the whole cohort. Sub-analyses were performed according to age greater or less than 80 years. The MDT managed 4617 patients over 14 years (1496 in the first interval and 1389 in the last). Over this time, there was a reduction in emergency resections from 15.5 per cent to 9.0 per cent (P < 0.0001); use of oncological therapies increased from 34.6 per cent to 41.6 per cent (P < 0.0001). The 90-day mortality after diagnosis of colorectal cancer dropped from 14.8 per cent to 10.7 per cent (P < 0.001) and 2-year survival improved from 58.6 per cent to 65 per cent (P < 0.001). Among patients aged 80 years or older (425 and 446, in the first and last intervals respectively) there was, in addition, a progressive increase in ‘no surgery’ rate from 33.6 per cent to 50.2 per cent (P < 0.0001) and a reduction in elective resections from 42.4 per cent to 33.9 per cent (P = 0.010). The 90-day mortality after elective resection fell from 10.0 per cent (18 of 180) to 3.3 per cent (5 of 151; P = 0.013). Survival from colorectal cancer improved significantly over 14 years. Among patients aged ≥80 years, major changes in the type of treatment delivered were associated with a decrease in postoperative mortality.
- Open Access
Excess Mortality by Multimorbidity, Socioeconomic, and Healthcare Factors, amongst Patients Diagnosed with Diffuse Large B-Cell or Follicular Lymphoma in England
(1) Background: Socioeconomic inequalities of survival in patients with lymphoma persist, which may be explained by patients’ comorbidities. We aimed to assess the association between comorbidities and the survival of patients diagnosed with diffuse large B-cell (DLBCL) or follicular lymphoma (FL) in England accounting for other socio-demographic characteristics. (2) Methods: Population-based cancer registry data were linked to Hospital Episode Statistics. We used a flexible multilevel excess hazard model to estimate excess mortality and net survival by patient’s comorbidity status, adjusted for sociodemographic, economic, and healthcare factors, and accounting for the patient’s area of residence. We used the latent normal joint modelling multiple imputation approach for missing data. (3) Results: Overall, 15,516 and 29,898 patients were diagnosed with FL and DLBCL in England between 2005 and 2013, respectively. Amongst DLBCL and FL patients, respectively, those in the most deprived areas showed 1.22 (95% confidence interval (CI): 1.18–1.27) and 1.45 (95% CI: 1.30–1.62) times higher excess mortality hazard compared to those in the least deprived areas, adjusted for comorbidity status, age at diagnosis, sex, ethnicity, and route to diagnosis. (4) Conclusions: Deprivation is consistently associated with poorer survival among patients diagnosed with DLBCL or FL, after adjusting for co/multimorbidities. Comorbidities and multimorbidities need to be considered when planning public health interventions targeting haematological malignancies in England.
Open AccessExcess Mortality by Multimorbidity, Socioeconomic, and Healthcare Factors, amongst Patients Diagnosed with Diffuse Large B-Cell or Follicular Lymphoma in England
(1) Background: Socioeconomic inequalities of survival in patients with lymphoma persist, which may be explained by patients’ comorbidities. We aimed to assess the association between comorbidities and the survival of patients diagnosed with diffuse large B-cell (DLBCL) or follicular lymphoma (FL) in England accounting for other socio-demographic characteristics. (2) Methods: Population-based cancer registry data were linked to Hospital Episode Statistics. We used a flexible multilevel excess hazard model to estimate excess mortality and net survival by patient’s comorbidity status, adjusted for sociodemographic, economic, and healthcare factors, and accounting for the patient’s area of residence. We used the latent normal joint modelling multiple imputation approach for missing data. (3) Results: Overall, 15,516 and 29,898 patients were diagnosed with FL and DLBCL in England between 2005 and 2013, respectively. Amongst DLBCL and FL patients, respectively, those in the most deprived areas showed 1.22 (95% confidence interval (CI): 1.18–1.27) and 1.45 (95% CI: 1.30–1.62) times higher excess mortality hazard compared to those in the least deprived areas, adjusted for comorbidity status, age at diagnosis, sex, ethnicity, and route to diagnosis. (4) Conclusions: Deprivation is consistently associated with poorer survival among patients diagnosed with DLBCL or FL, after adjusting for co/multimorbidities. Comorbidities and multimorbidities need to be considered when planning public health interventions targeting haematological malignancies in England.
- 1 April 2021
- Published by Elsevier in Cancer Epidemiology
- Vol. 71, 101896
Exploring socioeconomic differences in surgery and in time to elective surgery for colon cancer in England: Population-based study
- 1 April 2021
- Published by Elsevier in Cancer Epidemiology
- Vol. 71, 101896
Exploring socioeconomic differences in surgery and in time to elective surgery for colon cancer in England: Population-based study
- Open Access
- 8 December 2020
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 50 (2) , 696
Reply to: Versatility of the clone-censor-weight approach: response to ‘‘trial emulation in the presence of immortal-time bias’’
We thank Zhao et al. 1 for their interest in our recent article 2 which aims to provide a step-by-step tutorial for the design and analysis of emulated target clinical trials from observational data, to prevent immortal-time bias. In particular, we would like to thank the authors for illustrating the versatility of the concept of cloning within the trial emulation framework by describing a wide range of applications.
- 8 December 2020
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 50 (2) , 696
Open AccessReply to: Versatility of the clone-censor-weight approach: response to ‘‘trial emulation in the presence of immortal-time bias’’
We thank Zhao et al. 1 for their interest in our recent article 2 which aims to provide a step-by-step tutorial for the design and analysis of emulated target clinical trials from observational data, to prevent immortal-time bias. In particular, we would like to thank the authors for illustrating the versatility of the concept of cloning within the trial emulation framework by describing a wide range of applications.